IL-6-induced Activation of MYC is Responsible for the Down-regulation of CD33 Expression in CD33+ Myeloma Cells

Overview

Journal Int J Hematol

Specialty Hematology

Date 2009 Mar 5

PMID 19259613

Citations 6

Authors

Karim Shamsasenjan

Ken-Ichiro Otsuyama

Saeid Abroun

Mohd S Iqbal

Maged S Mahmoud

Hideki Asaoku

Michio M Kawano

Affiliations

Soon will be listed here.

Abstract

Human myeloma cells from about 10% of cases with multiple myeloma expressed CD33 and had monocytoid morphology with convoluted nuclei, and all these patients had no increase in serum CRP values. In CD33(+) myeloma cells as well as myeloma cell lines, CD33 expression levels were correlated with the increased expression levels of CEBPA (C/EBPalpha). This correlation was confirmed by the finding that transfection with the CEBPA gene induced CD33 expression in a CD33(-) myeloma cell line. As suggested by the lack of an increase in serum CRP values in CD33(+) myelomas, IL-6 down-regulated the expression of CD33 in CD33(+) myeloma cell lines along with the down-regulation of CEBPA gene expression. Cucurbitacin I (STAT3 inhibitor), but not U0126 (MAPK inhibitor), could abolish the effect of IL-6. Furthermore, IL-6 up-regulated the expression of MYC via STAT3 phosphorylation and MYC bound to the promoter region of the CEBPA gene followed by the down-regulation of CEBPA expression. It was confirmed that introduction of shRNA for MYC into a CD33(+) myeloma cell line blocked the IL-6-induced down-regulation of CD33 and CEBPA expression. Therefore, these results indicate that IL-6 can reverse the expression level of CD33 by up-regulating MYC followed by the down-regulation of CEBPA expression.

Citing Articles

CD33 is downregulated by influenza virus H1N1pdm09 and induces ROS and the TNF-α, IL-1β, and IL-6 cytokines in human mononuclear cells.

Guzman-Beltran S, Herrera M, Torres M, Gonzalez Y Braz J Microbiol. 2022; 53(1):89-97.

PMID: 35075617 PMC: 8882749. DOI: 10.1007/s42770-021-00663-4.

Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis.

Bo C, Zhang H, Cao Y, Lu X, Zhang C, Li S Sci Rep. 2021; 11(1):2416.

PMID: 33510225 PMC: 7843995. DOI: 10.1038/s41598-021-81962-6.

Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases.

Liu T, Zhou Y, Ko K, Yang H Mediators Inflamm. 2015; 2015:276850.

PMID: 26508814 PMC: 4609837. DOI: 10.1155/2015/276850.

Nordihydroguaiaretic acid attenuates the oxidative stress-induced decrease of CD33 expression in human monocytes.

Guzman-Beltran S, Pedraza-Chaverri J, Gonzalez-Reyes S, Hernandez-Sanchez F, Juarez-Figueroa U, Gonzalez Y Oxid Med Cell Longev. 2013; 2013:375893.

PMID: 23533689 PMC: 3596923. DOI: 10.1155/2013/375893.

High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes.

Gonzalez Y, Herrera M, Soldevila G, Garcia-Garcia L, Fabian G, Perez-Armendariz E BMC Immunol. 2012; 13:19.

PMID: 22500980 PMC: 3353220. DOI: 10.1186/1471-2172-13-19.

References

Sahara N, Ohnishi K, Ono T, Sugimoto Y, Kobayashi M, Takeshita K . Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. Eur J Haematol. 2006; 77(1):14-8. DOI: 10.1111/j.1600-0609.2006.00661.x. View

Harada H, Kawano M, Huang N, Harada Y, Iwato K, TANABE O . Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993; 81(10):2658-63. View

Liu S, Ishikawa H, Li F, Ma Z, Otsuyama K, Asaoku H . Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma. Cancer Res. 2005; 65(6):2269-76. DOI: 10.1158/0008-5472.CAN-04-3079. View

Liu S, Otsuyama K, Ma Z, Abroun S, Shamsasenjan K, Amin J . Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6. Int J Hematol. 2007; 85(1):49-58. DOI: 10.1532/IJH97.06132. View

Crocker P, Varki A . Siglecs, sialic acids and innate immunity. Trends Immunol. 2001; 22(6):337-42. DOI: 10.1016/s1471-4906(01)01930-5. View

Crocker P . Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol. 2002; 12(5):609-15. DOI: 10.1016/s0959-440x(02)00375-5. View

Peiper S, Ashmun R, Look A . Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988; 72(1):314-21. View

Zada A, Pulikkan J, Bararia D, Geletu M, Trivedi A, Balkhi M . Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link. Leukemia. 2006; 20(12):2137-46. DOI: 10.1038/sj.leu.2404438. View

Lin K, Angelin-Duclos C, Kuo T, Calame K . Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002; 22(13):4771-80. PMC: 133916. DOI: 10.1128/MCB.22.13.4771-4780.2002. View

10.

Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M . The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992; 12(6):2662-72. PMC: 364460. DOI: 10.1128/mcb.12.6.2662-2672.1992. View

11.

Kawano M, Mahmoud M, Ishikawa H . Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. Br J Haematol. 1997; 99(1):131-8. DOI: 10.1046/j.1365-2141.1997.3473161.x. View

12.

Klein B, Zhang X, Jourdan M, Content J, Houssiau F, Aarden L . Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989; 73(2):517-26. View

13.

Antonson P, Pray M, Jacobsson A, Xanthopoulos K . Myc inhibits CCAAT/enhancer-binding protein alpha-gene expression in HIB-1B hibernoma cells through interactions with the core promoter region. Eur J Biochem. 1995; 232(2):397-403. DOI: 10.1111/j.1432-1033.1995.397zz.x. View

14.

Bodger M, Hart D . Molecular cloning and functional analysis of the CD33 promoter. Br J Haematol. 1998; 102(4):986-95. DOI: 10.1046/j.1365-2141.1998.00863.x. View

15.

Legraverend C, Antonson P, Flodby P, Xanthopoulos K . High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucleic Acids Res. 1993; 21(8):1735-42. PMC: 309408. DOI: 10.1093/nar/21.8.1735. View

16.

Shimizu S, Takiguchi T, Fukutoku M, Yoshioka R, Hirose Y, Fukuhara S . Establishment of a CD4-positive plasmacytoma cell line (AMO1). Leukemia. 1993; 7(2):274-80. View

17.

Spier C, Grogan T, Durie B, Richter L, Vela E, Frutiger Y . T-cell antigen-positive multiple myeloma. Mod Pathol. 1990; 3(3):302-7. View

18.

Ruiz-Arguelles G, San Miguel J . Cell surface markers in multiple myeloma. Mayo Clin Proc. 1994; 69(7):684-90. DOI: 10.1016/s0025-6196(12)61350-0. View

19.

Mateo G, Castellanos M, Rasillo A, Gutierrez N, Montalban M, Martin M . Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005; 11(10):3661-7. DOI: 10.1158/1078-0432.CCR-04-1489. View

20.

Nagai T, Ogura M, Morishita Y, Okumura M, Kato Y, Morishima Y . Establishment and characterization of a new human Bence Jones-type myeloma cell line, NOP-2. Int J Hematol. 1991; 54(2):141-9. View